Literature DB >> 21798995

Gene expression profile of human thyroid cancer in relation to its mutational status.

Dagmara Rusinek1, Sylwia Szpak-Ulczok, Barbara Jarzab.   

Abstract

This review describes the gene expression profile changes associated with the presence of different mutations that contribute to thyroid cell carcinogenesis. The results are discussed in the context of thyroid cancer biology and of the implications for disease prognosis, while the diagnostic aspect has been omitted. For papillary thyroid cancer (PTC), the most characteristic gene expression profile is associated with the presence of BRAF mutation. BRAF-associated PTC differ profoundly from RET/PTC or RAS-associated cancers. Simultaneously, they retain many characteristic gene expression features common for all PTCs, induced by the alternative mutations activating MAPK pathway. Although the difference between papillary and follicular thyroid cancer (FTC) is significant at the gene expression profile level, surprisingly, the RAS-related signature of FTC is not well specified. PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements, which occur in FTC as an alternative to the RAS mutation, are associated with specific changes in gene expression. Furthermore, the difference between well-differentiated thyroid cancers and poorly differentiated and anaplastic thyroid cancers is mainly a reflection of tumor degree of differentiation and may not be attributed to the presence of characteristic mutations.
© 2011 Society for Endocrinology

Entities:  

Mesh:

Year:  2011        PMID: 21798995     DOI: 10.1530/JME-11-0023

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  14 in total

1.  Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.

Authors:  Naoyoshi Onoda; Masanori Nakamura; Naoki Aomatsu; Satoru Noda; Shinichiro Kashiwagi; Kento Kurata; Shinya Uchino; Kosei Hirakawa
Journal:  Mol Clin Oncol       Date:  2015-01-23

2.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

Authors:  Christina A von Roemeling; Laura A Marlow; Anthony B Pinkerton; Angela Crist; James Miller; Han W Tun; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2015-02-12       Impact factor: 5.958

Review 4.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

Review 5.  Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

Authors:  Christina A von Roemeling; John A Copland
Journal:  Expert Opin Ther Targets       Date:  2015-09-28       Impact factor: 6.902

Review 6.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

7.  Polymorphisms of IL-4 and IL-4R are associated to some demographic characteristics of differentiated thyroid cancer patients but are not determinants of risk in the Brazilian population.

Authors:  Mariana Bonjiorno Martins; Fernando de Assis Batista; Natassia Elena Bufalo; Karina Colombera Peres; Murilo Meneghetti; Ligia Vera Montali da Assumpção; Laura Sterian Ward
Journal:  Endocrine       Date:  2020-09-09       Impact factor: 3.633

Review 8.  MEK genomics in development and disease.

Authors:  Jennifer L Bromberg-White; Nicholas J Andersen; Nicholas S Duesbery
Journal:  Brief Funct Genomics       Date:  2012-06-29       Impact factor: 4.241

9.  Transcriptome analysis discloses dysregulated genes in normal appearing tumor-adjacent thyroid tissues from patients with papillary thyroid carcinoma.

Authors:  Huiling He; Sandya Liyanarachchi; Wei Li; Daniel F Comiskey; Pearlly Yan; Ralf Bundschuh; Altan M Turkoglu; Pamela Brock; Matthew D Ringel; Albert de la Chapelle
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

Review 10.  Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.

Authors:  Rosalba Parenti; Lucia Salvatorelli; Gaetano Magro
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.